论文部分内容阅读
目的 探讨 P53基因突变与肺癌病理特征、预后、复发转移的关系。方法 聚合酶链反应 -单链构象多态性分析 (PCR- SSCP)方法检测 155例原发肺癌手术标本中 P53基因 5～ 8外显子突变。结果 小细胞肺癌 (SCL C) P53突变率 80 % ,非小细胞肺癌 (NSCL C) 53.8% (78/ 145)。 94例随访病人中 ,P53阳性组一年存活率为 6 8.6 0 % ,而 P53阴性组为 97.7% (P<0 .0 5)。P53突变组术后复发转移率 80 .6 % ,无突变组 2 8%。结论 P53突变是肺癌常见的基因异常。 SCL C突变率高于NSCL C。 P53突变与 NSCL C肿瘤大小、淋巴结转移及患者术后存活时间和复发转移关系密切 ,可作为 NSCL C预后判断的指标
Objective To investigate the relationship between P53 gene mutation and pathological characteristics, prognosis, recurrence and metastasis of lung cancer. Methods Polymerase chain reaction-single strand conformation polymorphism analysis (PCR-SSCP) was used to detect mutations in exon 5-8 of P53 gene in 155 primary lung cancer specimens. Results The mutation rate of P53 was 80% in small cell lung cancer (SCL C) and 53.8% (78/145) in non-small cell lung cancer (NSCL C). Among the 94 patients followed up, the one-year survival rate of the P53-positive group was 68.60%, while that of the P53-negative group was 97.7% (P<0.05). The rate of postoperative recurrence and metastasis in the P53 mutation group was 80.6 %, and it was 28% in the non-mutation group. Conclusion P53 mutation is a common genetic abnormality in lung cancer. The SCL C mutation rate is higher than that of NSCL C. P53 mutation is closely related to NSCL C tumor size, lymph node metastasis, and postoperative survival time and recurrence and metastasis. It can be used as an indicator of prognosis of NSCL C.